Shuichi Kanazashi
Direktor/Vorstandsmitglied bei SATSUMA PHARMACEUTICALS, INC.
Aktive Positionen von Shuichi Kanazashi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Vertrieb & Marketing | 01.04.2020 | - |
Direktor/Vorstandsmitglied | 01.06.2014 | 29.06.2016 | |
Corporate Officer/Principal | 01.04.2014 | 01.04.2020 | |
SATSUMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 08.06.2023 | - |
Karriereverlauf von Shuichi Kanazashi
Ehemalige bekannte Positionen von Shuichi Kanazashi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UMN PHARMA INC. | Gründer | 20.04.2004 | 01.03.2012 |
Präsident | 01.01.2005 | 01.03.2012 | |
SONY GROUP CORPORATION | Corporate Officer/Principal | - | - |
Nippon Roche KK
Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Corporate Officer/Principal | - | - |
Ausbildung von Shuichi Kanazashi
Kyoto University | Doctorate Degree |
Statistik
International
Japan | 6 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Founder | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
SONY GROUP CORPORATION | Electronic Technology |
Private Unternehmen | 3 |
---|---|
UMN Pharma, Inc.
UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
Nippon Roche KK
Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Health Technology |
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Shuichi Kanazashi
- Erfahrung